Prospective Black volunteers who showed early symptoms of disease did not meet the required level of amyloid in their brain to qualify for trials, according to 10 researchers. Hispanic individuals, who experience dementia at a higher rate than white individuals, were also excluded at a slightly higher rate due to low levels of amyloid. This disparity in amyloid levels is raising concerns among scientists about who will benefit from the two newly developed treatments that have been proven to slow cognitive decline. Researchers are questioning whether Black patients are experiencing dementia due to causes other than Alzheimer’s or if the disease manifests differently in diverse populations with higher rates of chronic conditions. The discrepancy in beta amyloid levels suggests that certain health metrics may not function the same way in diverse populations as they do in white individuals. Some pharmaceutical companies are working to understand why Black individuals were screened out of clinical trials for the new treatments due to insufficient amyloid levels. The US Food and Drug Administration encourages companies to increase the enrollment of diverse populations in ongoing trials. Clinical trials typically have low enrollment rates of diverse populations, with white individuals comprising around 80% of participants and Black individuals only 10%. Researchers are calling for a better understanding of Alzheimer’s in Black individuals to ensure effective treatments are available to this at-risk population. Differences in amyloid levels may be influenced by genetic factors such as the APOE4 variant, as well as socioeconomic factors and health disparities. Recent studies are exploring the impact of racism and inequities in income, access to healthcare, and exposure to stress on the health and biology of different populations.
Experts say new Alzheimer’s drugs may have greater benefits for Caucasian Americans compared to African Americans
Denial of responsibility! Swift Telecast is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – swifttelecast.com. The content will be deleted within 24 hours.